Steven M. Pieper Net Worth

The estimated Net Worth of Steven Pieper is at least 3.37 百万$ dollars as of 20 November 2023. Mr Pieper owns over 28,000 units of Xeris Biopharma Inc stock worth over 3,365,968$ and over the last 3 years he sold XERS stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Pieper XERS stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Xeris Biopharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of XERS stock worth 54,600$ on 20 November 2023.

The largest trade he's ever made was buying 28,000 units of Xeris Biopharma Inc stock on 20 November 2023 worth over 54,600$. On average, Mr trades about 6,625 units every 93 days since 2021. As of 20 November 2023 he still owns at least 1,176,912 units of Xeris Biopharma Inc stock.

You can see the complete history of Mr Pieper stock trades at the bottom of the page.

Mr. Steven M. Pieper biography

Steven M. Pieper is the Chief Financial Officer at Xeris Biopharma Inc.

How old is Mr Pieper?

Mr Pieper is 44, he's been the Chief Financial Officer of Xeris Biopharma Inc since . There are 19 older and no younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.

What's Mr Pieper's mailing address?

Steven's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.

Insiders trading at Xeris Biopharma Inc

Over the last 6 years, insiders at Xeris Biopharma Inc have traded over 2,845,230$ worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth 31,442,123$ . The most active insiders traders include Group, Llc Green Jeremy Red...、James E Deerfield Mgmt L.P....、Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of 197,048$. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth 10,159$.

What does Xeris Biopharma Inc do?

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Complete history of Mr Pieper stock trades at Xeris Biopharma Inc

Xeris Biopharma Inc executives and stock owners

Xeris Biopharma Inc executives and other stock owners filed with the SEC include:

• Paul Edick,
  Chairman of the Board, Chief Executive Officer
• John Shannon,
  President, Chief Operating Officer
• Paul R. Edick,
  Chairman & CEO
• Barry Deutsch,
  Chief Financial Officer
• John P. Shannon,
  Pres, COO & Director
• Beth Hecht,
  Senior Vice President, General Counsel, Corporate Secretary
• Beth P. Hecht J.D.,
  Sr. VP, Gen. Counsel, Corp. Sec. & Director
• John Schmid,
  Lead Independent Director
• BJ Bormann,
  Independent Director
• Marla Persky,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• Dawn Halkuff,
  Independent Director
• Mark Thierer,
  Independent Director
• Kenneth Johnson,
  Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
• Steven Prestrelski,
  Co-Founder, Chief Scientific Officer
• Dr. Steven J. Prestrelski MBA, Ph.D.,
  Co-Founder & Chief Scientific Officer
• Kevin McCulloch,
  Sr. VP of Global Operations & Bus. Devel.
• Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
  Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs
• Barry M. Deutsch,
  Exec. Officer
• Allison Wey,
  Sr. VP of Investor Relations & Corp. Communications
• Steven M. Pieper,
  Chief Financial Officer
• Dr. Steven J. Prestrelski,
  Co-Founder & Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt L.P....,
  
• Partners, Ltd.Palmetto Part...,
  
• Barbara Jean Anne Bormann K...,
  Director
• Jonathan Rigby,
  Director
• Kevin Mc Culloch,
  See Remarks
• Steven Pieper,
  See Remarks
• John Johnson,
  Director
• Garheng Kong,
  Director
• Ricki Louise Fairley,
  Director